Moreover, its overexpression is strongly correlated with the immunosuppressive tumor microenvironment, metastatic behavior, and poor patient outcomes, suggesting that TIMP1 could serve as a promising prognostic biomarker for CRC and CRLM. The gene discussed is TIMP1; the disease is neoplasm.